ArticleDrug metabolism and disposition: the biological fate of chemicals2025
Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters.
Article in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbiome-associated metabolites, valerobetaine and homocarnitine, inhibit carnitine transport via OCTN2.American journal of physiology. Cell physiology · 2026Article
- Population pharmacokinetic modeling of amisulpride drug interactions and a transporter binding analysis.European journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inhibition of renally expressed transport proteins such as organic cation transporter (OCT) 2 or multidrug and toxin extrusion protein (MATE) 1 can cause clinically relevant drug-drug interactions (DDIs). Endogenous biomarkers have been proposed as tools to characterize the DDI risk of new molecules in drug development. Many previously proposed biomarkers for OCT2/MATE1-mediated DDIs lack specificity and/or sensitivity indicating a need for additional, well characterized biomarkers. Recently, we demonstrated that treatment with cimetidine, a classical OCT/MATE-inhibitor, decreased the renal excretion of serotonin, tyramine, 1-methylhistamine, 5-amino valeric acid betaine, and 4-guanidinobutanoic acid in humans. So far, these compounds are incompletely characterized as substrates of OCT2, MATE1, and other drug transporters. We therefore used established cell models overexpressing OCT2 and/or MATE1, and cell models for other clinically important drug transporters (organic anion transporters 1 and 3, organic anion transporting polypeptides 1B1 and 1B3, and P-glycoprotein) to investigate the cellular uptake and/or vectorial transport of these 5 putative biomarkers. The in vitro results show that serotonin, tyramine, 1-methylhistamine, 5-amino valeric acid betaine, and 4-guanidinobutanoic acid are substrates of OCT2 and/or MATE1, supporting that the in vivo effect of cimetidine is due to inhibition of these transporters. Based on their transport by OCT2 and/or MATE1 compared to the minimal transport by other drug transporters and the in vivo effects of classical transport protein inhibitors in healthy volunteers, serotonin and 1-methylhistamine appear to be the most promising candidates for further validation as endogenous biomarkers for the early detection of clinically relevant OCT2- and MATE1-mediated renal DDIs. SIGNIFICANCE STATEMENT: This study characterizes 5 endogenous metabolites as substrates of the renally expressed transport proteins organic cation transporter (OCT) 2, multidrug and toxin extrusion protein (MATE) 1, and other important drug transporters. These transport proteins are known as important contributors to clinically observed drug-drug interactions. Of the respective 5 compounds, serotonin and 1-methylhistamine are the most promising candidates to be further investigated as biomarkers for interactions via OCT2/MATE1, which could improve drug-drug interaction assessment during clinical drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.